Research ExplorerPublicationsImpact of apoptotic circulating tumor cells (aCTC) in metast...

Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer

Standard

Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. / Deutsch, Thomas M; Riethdorf, Sabine; Nees, Juliane; Hartkopf, Andreas D; Schönfisch, Birgitt; Domschke, Christoph; Sprick, Martin R; Schütz, Florian; Brucker, Sara Y; Stefanovic, Stefan; Sohn, Christof; Pantel, Klaus; Trumpp, Andreas; Schneeweiss, Andreas; Wallwiener, Markus.

In: BREAST CANCER RES TR, Vol. 160, No. 2, 11.2016, p. 277-290.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Deutsch, TM, Riethdorf, S, Nees, J, Hartkopf, AD, Schönfisch, B, Domschke, C, Sprick, MR, Schütz, F, Brucker, SY, Stefanovic, S, Sohn, C, Pantel, K, Trumpp, A, Schneeweiss, A & Wallwiener, M 2016, 'Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer', BREAST CANCER RES TR, vol. 160, no. 2, pp. 277-290. https://doi.org/10.1007/s10549-016-3997-3

APA

Deutsch, T. M., Riethdorf, S., Nees, J., Hartkopf, A. D., Schönfisch, B., Domschke, C., Sprick, M. R., Schütz, F., Brucker, S. Y., Stefanovic, S., Sohn, C., Pantel, K., Trumpp, A., Schneeweiss, A., & Wallwiener, M. (2016). Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. BREAST CANCER RES TR, 160(2), 277-290. https://doi.org/10.1007/s10549-016-3997-3

Vancouver

Deutsch TM, Riethdorf S, Nees J, Hartkopf AD, Schönfisch B, Domschke C et al. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. BREAST CANCER RES TR. 2016 Nov;160(2):277-290. https://doi.org/10.1007/s10549-016-3997-3

Bibtex

@article{aad89fc502ac476989c219371857c204,
title = "Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer",
abstract = "PURPOSE: While intact circulating tumor cells (iCTC) have independent negative prognostic impact on patients with metastatic breast cancer (MBC), the prognostic relevance of apoptotic CTC (aCTC) has not been validated in larger patient cohorts. This study assessed aCTC and iCTC statuses at baseline (CTCBL) and CTC kinetics (CTCKIN) as changes from CTCBL to one completed treatment cycle for their utility in predicting response, progression-free survival (PFS), and overall survival (OS) in MBC.METHODS: Status of iCTC and aCTC was prospectively assessed in 442 patients using the CellSearch{\texttrademark} system. Different cutoffs were analyzed both for iCTC and aCTC (≥5, ≥10, ≥25 and ≥50 CTC/7.5 ml). CTCKIN were characterized by ≥25 % changes in CTC counts.RESULTS: Numbers of iCTC and aCTC at baseline correlated strongly (r = 0.7). For iCTCBL positive patients, additional detection of aCTCBL had a significant prognostic impact on OS (aCTCBL positive 10.3 vs. aCTCBL negative 16.4 months, p = 0.012). Worst prognosis for OS was observed in patients with ≥50 iCTC/7.5 ml and simultaneously detected aCTC. Determination of aCTCKIN showed stronger discriminating power than iCTCKIN, with higher PFS and OS for the group with decreasing CTCs (PFS 7.7 vs. 6.1; OS 22.2 vs. 16.4).CONCLUSIONS: Intact and aCTC are predictive of outcome in MBC. Apoptotic CTC counts ≥ 5/7.5 ml in conjunction with iCTC at baseline have an independent unfavorable prognostic impact on OS. Decreasing aCTCKIN at ≥ 5/7.5 ml in serial enumeration is associated with favorable outcome. Therefore, separate enumeration of iCTC and aCTC is useful in tailoring systemic treatment.",
author = "Deutsch, {Thomas M} and Sabine Riethdorf and Juliane Nees and Hartkopf, {Andreas D} and Birgitt Sch{\"o}nfisch and Christoph Domschke and Sprick, {Martin R} and Florian Sch{\"u}tz and Brucker, {Sara Y} and Stefan Stefanovic and Christof Sohn and Klaus Pantel and Andreas Trumpp and Andreas Schneeweiss and Markus Wallwiener",
year = "2016",
month = nov,
doi = "10.1007/s10549-016-3997-3",
language = "English",
volume = "160",
pages = "277--290",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer

AU - Deutsch, Thomas M

AU - Riethdorf, Sabine

AU - Nees, Juliane

AU - Hartkopf, Andreas D

AU - Schönfisch, Birgitt

AU - Domschke, Christoph

AU - Sprick, Martin R

AU - Schütz, Florian

AU - Brucker, Sara Y

AU - Stefanovic, Stefan

AU - Sohn, Christof

AU - Pantel, Klaus

AU - Trumpp, Andreas

AU - Schneeweiss, Andreas

AU - Wallwiener, Markus

PY - 2016/11

Y1 - 2016/11

N2 - PURPOSE: While intact circulating tumor cells (iCTC) have independent negative prognostic impact on patients with metastatic breast cancer (MBC), the prognostic relevance of apoptotic CTC (aCTC) has not been validated in larger patient cohorts. This study assessed aCTC and iCTC statuses at baseline (CTCBL) and CTC kinetics (CTCKIN) as changes from CTCBL to one completed treatment cycle for their utility in predicting response, progression-free survival (PFS), and overall survival (OS) in MBC.METHODS: Status of iCTC and aCTC was prospectively assessed in 442 patients using the CellSearch™ system. Different cutoffs were analyzed both for iCTC and aCTC (≥5, ≥10, ≥25 and ≥50 CTC/7.5 ml). CTCKIN were characterized by ≥25 % changes in CTC counts.RESULTS: Numbers of iCTC and aCTC at baseline correlated strongly (r = 0.7). For iCTCBL positive patients, additional detection of aCTCBL had a significant prognostic impact on OS (aCTCBL positive 10.3 vs. aCTCBL negative 16.4 months, p = 0.012). Worst prognosis for OS was observed in patients with ≥50 iCTC/7.5 ml and simultaneously detected aCTC. Determination of aCTCKIN showed stronger discriminating power than iCTCKIN, with higher PFS and OS for the group with decreasing CTCs (PFS 7.7 vs. 6.1; OS 22.2 vs. 16.4).CONCLUSIONS: Intact and aCTC are predictive of outcome in MBC. Apoptotic CTC counts ≥ 5/7.5 ml in conjunction with iCTC at baseline have an independent unfavorable prognostic impact on OS. Decreasing aCTCKIN at ≥ 5/7.5 ml in serial enumeration is associated with favorable outcome. Therefore, separate enumeration of iCTC and aCTC is useful in tailoring systemic treatment.

AB - PURPOSE: While intact circulating tumor cells (iCTC) have independent negative prognostic impact on patients with metastatic breast cancer (MBC), the prognostic relevance of apoptotic CTC (aCTC) has not been validated in larger patient cohorts. This study assessed aCTC and iCTC statuses at baseline (CTCBL) and CTC kinetics (CTCKIN) as changes from CTCBL to one completed treatment cycle for their utility in predicting response, progression-free survival (PFS), and overall survival (OS) in MBC.METHODS: Status of iCTC and aCTC was prospectively assessed in 442 patients using the CellSearch™ system. Different cutoffs were analyzed both for iCTC and aCTC (≥5, ≥10, ≥25 and ≥50 CTC/7.5 ml). CTCKIN were characterized by ≥25 % changes in CTC counts.RESULTS: Numbers of iCTC and aCTC at baseline correlated strongly (r = 0.7). For iCTCBL positive patients, additional detection of aCTCBL had a significant prognostic impact on OS (aCTCBL positive 10.3 vs. aCTCBL negative 16.4 months, p = 0.012). Worst prognosis for OS was observed in patients with ≥50 iCTC/7.5 ml and simultaneously detected aCTC. Determination of aCTCKIN showed stronger discriminating power than iCTCKIN, with higher PFS and OS for the group with decreasing CTCs (PFS 7.7 vs. 6.1; OS 22.2 vs. 16.4).CONCLUSIONS: Intact and aCTC are predictive of outcome in MBC. Apoptotic CTC counts ≥ 5/7.5 ml in conjunction with iCTC at baseline have an independent unfavorable prognostic impact on OS. Decreasing aCTCKIN at ≥ 5/7.5 ml in serial enumeration is associated with favorable outcome. Therefore, separate enumeration of iCTC and aCTC is useful in tailoring systemic treatment.

U2 - 10.1007/s10549-016-3997-3

DO - 10.1007/s10549-016-3997-3

M3 - SCORING: Journal article

C2 - 27696083

VL - 160

SP - 277

EP - 290

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 2

ER -